Enhertu vs Kadcyla

Enhertu (trastuzumab deruxtecan) is a HER2-directed antibody-drug conjugate reviewed for adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options, and for adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations and who have received a prior systemic therapy. The FDA review for Enhertu reported an Objective Response Rate (ORR) of 60.3% and a median Duration of Response (DoR) of 14.8 months.

Kadcyla (trastuzumab emtansine) is also a HER2-directed antibody-drug conjugate, reviewed for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane. The EMA review for Kadcyla reported an IRC-assessed Objective Response Rate (ORR) of 32.7% and a median duration of objective response of 9.7 months.

These drugs were studied in separate trials with different designs, patient populations, and timepoints. The figures presented are from each drug's own regulatory review documents and are not head-to-head comparisons. Neither drug is presented as superior to the other.